{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T21:31:32Z","timestamp":1777066292051,"version":"3.51.4"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009604","name":"Changchun Science and Technology Bureau","doi-asserted-by":"publisher","award":["21ZGM20"],"award-info":[{"award-number":["21ZGM20"]}],"id":[{"id":"10.13039\/501100009604","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS108"],"award-info":[{"award-number":["YDZJ202201ZYTS108"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In recent years, immune checkpoint inhibitors (ICIs) had extremely rapid growth in anti-cancer and improved outcomes of many malignancies, specifically lung cancer. However, the incidence of ICIs-related adverse events also raised. Using this meta-analysis, ICIs-related respiratory disorders were investigated in lung cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using Cochrane Library, Embase, and PubMed databases, we performed an integrated search for randomized controlled trials (RCTs) to compare respiratory disorders among different regimens. The data was prepared with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline, and the quality of included studies was evaluated based on the Cochrane manual.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 22 RCTs were involved in this meta-analysis. Compared with ICIs, chemotherapy reduced the risk of interstitial lung disease (p = 0.03; SMD: 2.81; 95% CI: 1.08, 7.27), pleural effusion (p = 0.002; SMD: 2.12; 95% CI: 1.32, 3.42), and pneumonitis (p &amp;lt; 0.00001; SMD: 9.23; 95% CI: 4.57, 18.64). ICIs plus chemotherapy could provide a higher probability for patients to suffer pneumonitis than chemotherapy (p = 0.01; SMD: 1.96; 95% CI: 1.17, 3.28). In addition, single ICI brought a lower likelihood for patients suffering pneumonitis than double ICIs (p = 0.004; SMD: 2.17; 95% CI: 1.27, 3.69).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ICIs-based treatment, such as ICIs alone, ICIs plus chemotherapy and double ICIs, can raise the incidences of some respiratory disorders in patients with lung cancer. It suggests that ICIs should be conducted based on a comprehensive consideration to prevent ICIs-related respiratory disorders. To a certain degree, this study might be provided to the clinician as a reference for ICIs practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022378901<\/jats:uri>, identifier (CRD42022378901).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1115305","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:51:03Z","timestamp":1678121463000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Han","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean X.","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"111ra20","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-79308-1_4","article-title":"Immunotherapy in lung cancer: Are the promises of long-term benefit finally met","volume":"1342","author":"Kaen","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80406-9","article-title":"Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells","volume":"7","author":"Chambers","year":"1997","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200526090","article-title":"Expression of lymphocyte activation gene 3 (LAG-3) on b cells is induced by T cells","volume":"35","author":"Kisielow","year":"2005","journal-title":"Eur J Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2478\/jtim-2021-0046","article-title":"Lung adenocarcinoma-specific three-integrin signature contributes to poor outcomes by metastasis and immune escape pathways","author":"Wang","year":"2021","journal-title":"J Transl Int Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejca.2016.12.041","article-title":"Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges","volume":"78","author":"Giroux Leprieur","year":"2017","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.6251","article-title":"The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"27","author":"Bishay","year":"2020","journal-title":"Curr Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.875093","article-title":"Inhibitors of PD-1 in non-small cell lung cancer: A meta-analysis of clinical and molecular features","volume":"13","author":"Huo","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000526141","article-title":"Risk factors for immune checkpoint inhibitor-related pneumonitis in cancer patients: A systemic review and meta-analysis","volume":"101","author":"Zhou","year":"2022","journal-title":"Respiration"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1013186","article-title":"Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: A systematic review and meta-analysis","volume":"13","author":"Kou","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.908173","article-title":"Cardiovascular toxicity with PD-1\/PD-L1 inhibitors in cancer patients: A systematic review and meta-analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B24","first-page":"470","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"316","author":"Irwig","year":"1998","journal-title":"Graphical test is itself biased Bmj"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-Small-Cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-Small-Cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-Positive non-Small-Cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-Small-Cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0409","article-title":"Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: The PROLUNG phase 2 randomized clinical trial","volume":"6","author":"Arrieta","year":"2020","journal-title":"JAMA Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-term overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN lung 200): an open-label, randomised, phase 3 study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non-Small-Cell lung cancer with PD-L1 tumor proportion score \u2265 50%: Randomized, double-blind phase III KEYNOTE-598 study","volume":"39","author":"Boyer","year":"2021","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-Small-Cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-Small-Cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-Small-Cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2209","article-title":"Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: The lung-MAP S1400I phase 3 randomized clinical trial","volume":"7","author":"Gettinger","year":"2021","journal-title":"JAMA Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-Selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2212Positive, advanced Non\u2212Small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-Small-Cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(\u2606)","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial","volume":"14","author":"Wu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.03.024","article-title":"Cancer immunotherapy: Current applications and challenges","volume":"480","author":"Sun","year":"2020","journal-title":"Cancer Lett"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-021-00833-8","article-title":"A review of cancer immunotherapy toxicity: Immune checkpoint inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J Med Toxicol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2018.07.002","article-title":"Cardiotoxicities associated with immune checkpoint inhibitors","volume":"42","author":"Yang","year":"2018","journal-title":"Curr Probl Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2019.07.008","article-title":"Cardiotoxicity of immune therapy","volume":"37","author":"Ganatra","year":"2019","journal-title":"Cardiol Clin"},{"key":"B69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40959-021-00106-x","article-title":"A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors","volume":"7","author":"Lal","year":"2021","journal-title":"Cardiooncology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","article-title":"Management of immune checkpoint inhibitor toxicities: A review and clinical guideline for emergency physicians","volume":"55","author":"Hryniewicki","year":"2018","journal-title":"J Emerg Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13141","article-title":"Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms","volume":"159","author":"Fessas","year":"2020","journal-title":"Immunology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"102031","DOI":"10.1016\/j.clinre.2022.102031","article-title":"Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials","volume":"46","author":"Yuan","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.028","article-title":"Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: A collaborative systematic review and meta-analysis","volume":"81","author":"Wu","year":"2022","journal-title":"Eur Urol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"13773","DOI":"10.1038\/s41598-020-70743-2","article-title":"Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study","volume":"10","author":"Okada","year":"2020","journal-title":"Sci Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.04.002","article-title":"Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: A multicenter prospective study","volume":"15","author":"Suzuki","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0050","article-title":"Pulmonary toxicity associated with erlotinib","volume":"132","author":"Liu","year":"2007","journal-title":"Chest"},{"key":"B78","article-title":"Analysis of the response and toxicity to gefitinib of non-small cell lung cancer","volume":"25","author":"Konishi","year":"2005","journal-title":"Anticancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-007-0106-4","article-title":"Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment","volume":"9","author":"Grande","year":"2007","journal-title":"Clin Transl Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016214032272","article-title":"A report on serious pulmonary toxicity associated with gemcitabine-based therapy","volume":"20","author":"Roychowdhury","year":"2002","journal-title":"Invest New Drugs"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1159\/000336131","article-title":"Interstitial pneumonitis after treatment with pemetrexed: A rare event","volume":"58","author":"Hochstrasser","year":"2012","journal-title":"Chemotherapy"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2009.n.050","article-title":"Pemetrexed-induced pneumonitis: A case report","volume":"10","author":"Loriot","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000577","article-title":"Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: A retrospective observational cohort study with a systematic literature review","volume":"10","author":"Cr\u00e9quit","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1186\/s12885-019-6138-7","article-title":"Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: Potential role of Th1-dominant immune response in immune-related adverse events: two case reports","volume":"19","author":"Yoshino","year":"2019","journal-title":"BMC Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-Based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.12.019","article-title":"Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab recativity","volume":"86","author":"Tanaka","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20894","article-title":"Interleukin-23\/Th17 pathways and inflammatory bowel disease","volume":"15","author":"Abraham","year":"2009","journal-title":"Inflammation Bowel Dis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2007.00874.x","article-title":"Serum levels of tumour necrosis factor-alpha and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate\u2013preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy","volume":"17","author":"Grim-Stieger","year":"2008","journal-title":"Eur J Cancer Care (Engl)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.503773","article-title":"Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia","volume":"10","author":"Penna","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"B92","doi-asserted-by":"publisher","first-page":":1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated interstitial Lung Dis Cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"B93","doi-asserted-by":"publisher","first-page":"100156","DOI":"10.1016\/j.jtocrr.2021.100156","article-title":"Progressive pleural effusion as an immune-related adverse event in NSCLC: A case report","volume":"2","author":"Shen","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.7219-21","article-title":"Late-onset pleural and pericardial effusion as immune-related adverse events after 94 cycles of nivolumab","volume":"60","author":"Sawada","year":"2021","journal-title":"Intern Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","article-title":"Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases","volume":"4","author":"Kolla","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-Small-Cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7629","article-title":"Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-Small-Cell lung cancer","volume":"35","author":"Govindan","year":"2017","journal-title":"J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2013.33.e280","article-title":"Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer","volume":"33","author":"Chow","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: A systematic review and meta-analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.10.013","article-title":"Analysis of factors associated with in-hospital mortality in lung cancer chemotherapy patients with neutropenia","volume":"19","author":"Cupp","year":"2018","journal-title":"Clin Lung Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1115305\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:51:12Z","timestamp":1678121472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1115305\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":117,"alternative-id":["10.3389\/fimmu.2023.1115305"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1115305","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"article-number":"1115305"}}